Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

A composite single-nucleotide polymorphism prediction signature for extranodal natural killer/T-cell lymphoma

Blood blood.2020010637.

DOI: https://doi.org/10.1182/blood.2020010637

Published: 2021

Includes: Supplemental data

Journal Articles

Synergistic Antitumor Effect and Mechanism of Chidamide Combined with Gemcitabine, Oxaliplatin or Zanubrutinib in Diffuse Large B-Cell Lymphoma

Qingqing Cai, PhD, Tianying Huang, Master, Ning Su, MM, Xiaolu Xu, Master, Fengwei Wang, Doctor, Yu Fang, BMBS, Xiaopeng Tian, MDPhD, Jun Cai, BMBS, Shuyun Ma, MM, Yang Liang, PhD

Blood (2020) 136 (Supplement 1): 14–15.

DOI: https://doi.org/10.1182/blood-2020-133487

Published: 2020

Journal Articles

Efficacy and Safety Analysis of Ibrutinib-Containing Therapy for Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results from a Real-World Study in China

Blood (2020) 136 (Supplement 1): 1.

DOI: https://doi.org/10.1182/blood-2020-136842

Published: 2020

Journal Articles

Safety and Preliminary Efficacy of Sintilimab Plus P-Gemox (Pegaspargase, Gemcitabine and Oxaliplatin) Regimen As First-Line Treatment for Patients with Advanced Extranodal Natural Killer/T Cell Lymphoma, Nasal Type: An Open-Label, Multicenter, Phase 2 Study

Qingqing Cai, PhD, Huiqiang Huang, MDPhD, Panpan Liu, MD PhD, Hui Zhou, MD PhD, Yajun Li, MD PhD, Yujing Zhang, MD PhD, Lixia Lu, MD PhD, Yan Gao, MD PhD, Xuanye Zhang, MDPhD, Yi Xia, MD PhD, Jun Cai, BMBS, Ning Su, MM, Shuyun Ma, MM, Hang Yang, MD PhD, Yu Fang, BMBS

Blood (2020) 136 (Supplement 1): 26–27.

DOI: https://doi.org/10.1182/blood-2020-136949

Published: 2020

Journal Articles

The Expression of Paks and Its Clinical Significance in T-Cell Lymphoblastic Lymphoma

Qingqing Cai, PhD, Ning Su, MM, Yu Fang, BMBS, Xu Chen, MDPhD, Xiaopeng Tian, MDPhD, Shuyun Ma, MM, Xiaoqin Chen, MDPhD, Zhongjun Xia, MDPhD, Tongyu Lin, MD PhD, Huiqiang Huang, MDPhD, Zhiming Li, MD PhD, Xueyi Pan, MDPhD, Yi Xia, MD PhD, Panpan Liu, MD PhD, Xuanye Zhang, MDPhD, Hang Yang, MD PhD, Stephen Yang Liang, MDPhD

Blood (2020) 136 (Supplement 1): 14–16.

DOI: https://doi.org/10.1182/blood-2020-136975

Published: 2020

Journal Articles

Chidamide Plus R-GemOx(rituximab, gemcitabine and oxaliplatin) Regimen As Salvage Treatment for Transplant-Ineligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Preliminary Analysis of a Multicenter, Single Arm, Phase II Study

Qingqing Cai, PhD, Hui Zhou, MDPhD, Zhiming Li, MD PhD, Wenyu Li, PhD, Yudan Wu, MDPhD, Bingyi Wu, MDPhD, Hui Yang, MDPhD, Stephen Yang Liang, MDPhD, Ning Su, MM, Panpan Liu, MD PhD, Xuanye Zhang, MDPhD, Yi Xia, MD PhD, Shuyun Ma, MM

Blood (2020) 136 (Supplement 1): 52–53.

DOI: https://doi.org/10.1182/blood-2020-136993

Published: 2020

Journal Articles

Clinical Outcome of P-Gemox ( Pegaspargase, Gemcitabine, Oxaliplatin ) for the Patients with Newly Diagnosed Stage III/IV or Relapsed/Refractory Extranodal Natural Killer/T Cell Lymphoma

Huiqiang Huang, MD, Yan Gao, XiaoXiao Wang, Qingqing Cai, MD, QiChun Cai, Bing Bai, Wei Zhao, Zheng Yan, Wenqi Jiang, MD PhD, Zhongjun Xia, MD, ZhiMing Li

Blood (2015) 126 (23): 1521.

DOI: https://doi.org/10.1182/blood.V126.23.1521.1521

Published: 2015

Journal Articles

Lenalidomide Plus Rituximab for Relapsed or Refractory Diffuse Large B-Cell, Follicular and Transformed Lymphoma: Final Data Analysis of a Phase 2 Trial

Blood (2015) 126 (23): 3969.

DOI: https://doi.org/10.1182/blood.V126.23.3969.3969

Published: 2015

Journal Articles

Longterm Outcome of Induction Chemotherapy of P-Gemox Regimen Followed By Extensive Involved-Field Radiotherapy(EIFRT) for Newly Diagnosed Stage I/II Extranodal Natural Killer/T-Cell Lymphoma---a Single Center Experience

Huiqiang Huang, MD, Yan Gao, XiaoXiao Wang, Qingqing Cai, MD, QiChun Cai, Bing Bai, Zheng Yan, Wenqi Jiang, Zhongjun Xia, MD, ZhiMing Li

Blood (2015) 126 (23): 3936.

DOI: https://doi.org/10.1182/blood.V126.23.3936.3936

Published: 2015

Journal Articles

The Identification of Novel Therapies for the Treatment of Follicular Dendritic Cell Sarcoma

Bo Wang, MD, Liang Zhang, MD PhD, Lan Pham, PhD, Wenjing Tao, PhD, Hui Zhang, Jingmeng Xie, Wendy Chen, Qingqing Cai, MD PhD, Dehui Zou, MD PhD, Donglu Zhao, MD, Xiuhua Sun, MDPhD, Rong Liang, MD PhD, Jack Wang, Krystle Nomie, PhD, Nathan Fowler, MD, Michael Wang, MD

Blood (2015) 126 (23): 5126.

DOI: https://doi.org/10.1182/blood.V126.23.5126.5126

Published: 2015

Journal Articles

Microrna-374b Suppresses Proliferation and Promotes Apoptosis in T-Cell Lymphoblastic Lymphoma By Repressing Wnt-16 and AKT1 and Is a Promising Predictive Biomarker for Patients Survival

Qingqing Cai, MD PhD, Dong Qian, MD PhD, Kailin Chen, MD, Dan Xie, MD PhD, Huilan Rao, MDPhD, Huiqiang Huang, MD, Xiaofei Sun, MD

Blood (2014) 124 (21): 1638.

DOI: https://doi.org/10.1182/blood.V124.21.1638.1638

Published: 2014

Journal Articles

A Novel and Significant Predictor in Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: The Prognostic Nutritional Index (PNI)

Qingqing Cai, MD PhD, Kailin Chen, MD, Huilan Rao, MDPhD, Wenqi Jiang, MD PhD, Huiqiang Huang, MD, Tongyu Lin, MDPhD, Zhongjun Xia, MD

Blood (2014) 124 (21): 1650.

DOI: https://doi.org/10.1182/blood.V124.21.1650.1650

Published: 2014

Journal Articles

Hepatitis B e Antibody Positive before Rituximab Combination Chemotherapy Is Associated with a Lower Risk of Hepatitis B Virus (HBV) Reactivation in HBV Carriers with Diffuse Large B-Cell Lymphoma

Qingqing Cai, MD PhD, Kailin Chen, MD, Qirong Geng, MD, Guangzheng Zhong, MD, Jianping Li, MD, Huiqiang Huang, MD, Tongyu Lin, MDPhD, Wenqi Jiang, MD PhD, Zhiming Li, MD PhD

Blood (2014) 124 (21): 1655.

DOI: https://doi.org/10.1182/blood.V124.21.1655.1655

Published: 2014

Journal Articles

Potent Inhibition of the Growth and Induction of Apoptosis of Mantle Cell Lymphoma By the Novel Anthracycline Berubicin in Vitro and in Vivo

George Tsourdinis, Hyebin Park, Luhong Sun, MD PhD, Izabela Fokt, PhD, Arumugam Jayakumar, MSc, PhD, Hui Zhang, Qingqing Cai, MD PhD, Dehui Zou, Bingliang Fang, MD PhD, Waldemar Priebe, PhD, Michael Wang, MD, Liang Zhang, MD PhD

Blood (2014) 124 (21): 3106.

DOI: https://doi.org/10.1182/blood.V124.21.3106.3106

Published: 2014

Journal Articles

The Activation Of M2 Polarized Tumor-Associated Macrophages In The Microenvironment Of NK/T-Cell Lymphoma and The Characteristics Of Cytokine Spectrum

Bing Bai, M.D., Ph.D., Hui-qiang Huang, M.D., Ph.D., Qi-chun Cai, M.D., Ph.D., Xiao-Xiao Wang, M.D, Ph.D., Qingqing Cai, M.D, Ph.D., Yan Gao, M.D., Wei Zhao, M.D.

Blood (2013) 122 (21): 4274.

DOI: https://doi.org/10.1182/blood.V122.21.4274.4274

Published: 2013

Journal Articles

Novel Combination Of Lenalidomide-Rituximab Provides An Effective Bridge To Stem Cell Transplantation In Relapsed and/Or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphomas: A Single Center Experience

Qingqing Cai, MD, PhD, Yiming Chen, MD., PhD., Dehui Zou, Maria Badillo, BS, Shouhao Zhou, PhD, Liang Zhang, MD, PhD, Elyse R Lopez, Wenqi Jiang, MD, PhD, Hui-qiang Huang, MD, PhD, Tongyu Lin, MD, PhD, Michael Wang, MD

Blood (2013) 122 (21): 3056.

DOI: https://doi.org/10.1182/blood.V122.21.3056.3056

Published: 2013

Journal Articles

The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma

Bing Bai, M.D., Ph.D., Hui-qiang Huang, M.D., Ph.D., Qi-chun Cai, M.D., Ph.D., Xiao-Xiao Wang, M.D, Ph.D., Qingqing Cai, M.D, Ph.D., Yan Gao, M.D., Wei Zhao, M.D.

Blood (2013) 122 (21): 1760.

DOI: https://doi.org/10.1182/blood.V122.21.1760.1760

Published: 2013

Journal Articles

A New Prognostic Model for Extranodal Natural Killer/T Cell Lymphoma, Nasal Type

Qingqing Cai, MD, PhD, Xiaolin Luo, MD, Ken H. Young, MD, Huiqiang Huang, MD, PhD, Guanrong Zhang, MD, Tongyu Lin, MD, PhD, Wenqi Jiang, MD, PhD, Zhongjun Xia, MD

Blood (2013) 122 (21): 1769.

DOI: https://doi.org/10.1182/blood.V122.21.1769.1769

Published: 2013

Journal Articles

Long-Term Outcome of Gemcitabine, Vinorelbine, Liposomal-Doxorubicin (GVD) As Salvage Regimen for Patients with Previously Heavily Treated Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphoma

Hui-qiang Huang, MD, PhD, Bing Bai, Qingqing Cai, Xu-Bin Lin, MD, Xiao-Xiao Wang, Qi-Chun Cai

Blood (2011) 118 (21): 1609.

DOI: https://doi.org/10.1182/blood.V118.21.1609.1609

Published: 2011

Journal Articles

Long-Term Outcomes of Patients with Newly Diagnosed NK/T-Cell Lymphoma Treated by EPOCH Regimen.

Huiqiang Huang, Zexiao Lin, Xubing Lin, Qingqing Cai, Zhongjun Xia, MD, Wenqi Jiang

Blood (2009) 114 (22): 2689.

DOI: https://doi.org/10.1182/blood.V114.22.2689.2689

Published: 2009

NARROW

A composite single-nucleotide polymorphism prediction signature for extranodal natural killer/T-cell lymphoma

Synergistic Antitumor Effect and Mechanism of Chidamide Combined with Gemcitabine, Oxaliplatin or Zanubrutinib in Diffuse Large B-Cell Lymphoma

Efficacy and Safety Analysis of Ibrutinib-Containing Therapy for Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results from a Real-World Study in China

Safety and Preliminary Efficacy of Sintilimab Plus P-Gemox (Pegaspargase, Gemcitabine and Oxaliplatin) Regimen As First-Line Treatment for Patients with Advanced Extranodal Natural Killer/T Cell Lymphoma, Nasal Type: An Open-Label, Multicenter, Phase 2 Study

The Expression of Paks and Its Clinical Significance in T-Cell Lymphoblastic Lymphoma

Chidamide Plus R-GemOx(rituximab, gemcitabine and oxaliplatin) Regimen As Salvage Treatment for Transplant-Ineligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Preliminary Analysis of a Multicenter, Single Arm, Phase II Study

Clinical Outcome of P-Gemox ( Pegaspargase, Gemcitabine, Oxaliplatin ) for the Patients with Newly Diagnosed Stage III/IV or Relapsed/Refractory Extranodal Natural Killer/T Cell Lymphoma

Lenalidomide Plus Rituximab for Relapsed or Refractory Diffuse Large B-Cell, Follicular and Transformed Lymphoma: Final Data Analysis of a Phase 2 Trial

Longterm Outcome of Induction Chemotherapy of P-Gemox Regimen Followed By Extensive Involved-Field Radiotherapy(EIFRT) for Newly Diagnosed Stage I/II Extranodal Natural Killer/T-Cell Lymphoma---a Single Center Experience

The Identification of Novel Therapies for the Treatment of Follicular Dendritic Cell Sarcoma

Microrna-374b Suppresses Proliferation and Promotes Apoptosis in T-Cell Lymphoblastic Lymphoma By Repressing Wnt-16 and AKT1 and Is a Promising Predictive Biomarker for Patients Survival

A Novel and Significant Predictor in Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: The Prognostic Nutritional Index (PNI)

Hepatitis B e Antibody Positive before Rituximab Combination Chemotherapy Is Associated with a Lower Risk of Hepatitis B Virus (HBV) Reactivation in HBV Carriers with Diffuse Large B-Cell Lymphoma

Potent Inhibition of the Growth and Induction of Apoptosis of Mantle Cell Lymphoma By the Novel Anthracycline Berubicin in Vitro and in Vivo

The Activation Of M2 Polarized Tumor-Associated Macrophages In The Microenvironment Of NK/T-Cell Lymphoma and The Characteristics Of Cytokine Spectrum

Novel Combination Of Lenalidomide-Rituximab Provides An Effective Bridge To Stem Cell Transplantation In Relapsed and/Or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphomas: A Single Center Experience

The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma

A New Prognostic Model for Extranodal Natural Killer/T Cell Lymphoma, Nasal Type

Long-Term Outcome of Gemcitabine, Vinorelbine, Liposomal-Doxorubicin (GVD) As Salvage Regimen for Patients with Previously Heavily Treated Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphoma

Long-Term Outcomes of Patients with Newly Diagnosed NK/T-Cell Lymphoma Treated by EPOCH Regimen.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only